Anti-tumor immunotherapy in veterinary medicine

Allana Talita Schoenfelder; Lucas Airto Belarmino; Keila Zaniboni Siqueira Batista

doi:10.29327/multi.2021010

Keywords:

monoclonal antibodies

adaptive immunity

immune system

immune reconstitution

vaccine therapy

Abstract

Neoplasm treatment is carried out mainly through surgery, chemotherapy, and radiotherapy. However, despite general progress in cancer therapy, effective treatment options and even healing are still insufficient for certain cancer patients. Anti-tumor immunotherapy fits this gap since it consists of the immune system manipulating to identify and destroy neoplastic cells. In this context, the present study aims to review the literature on anti-tumor immunotherapy in veterinary medicine, side effects, and other aspects considered relevant to the different methods. Besides, the evaluation of the response pattern presented and the cells and components involved were considered. For this purpose, the search sites Medline, Scielo, and Portal CAPES were used, using the following keywords: anti-tumor immunotherapy, antineoplastic antibodies, and anticancer vaccines, for the selection of scientific articles from the last ten years. Although immunotherapy acts differently from any other type of cancer treatment, its indication is related to the tumor’s characteristics and the treatment stage in which the patient is. The literature covers the study of different anti-tumor immunotherapy strategies focusing on application in humans; however, most of the tests and responses evaluated occur in other animal species. Thus, the potential for using anti-tumor immunotherapy in veterinary medicine is clear, to stimulate immune system responses against cancer cells, preventing tumor amplification and dissemination.
References
1. Berger M (2005) Estudo de fase I com vacina celular autóloga imunomodulada para tratamento de câncer de próstata localmente avançado ou metastático. Thesis, Universidade Federal do Rio Grande do Sul.
2. Bowers JS, Majchrzak K, Nelson MH, Aksoy BA, Wyatt MM, Smith, AS, Bailey SR, Neal LR, Hammerbacher JE, Paulos CM (2017) PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T Cells. Frontiers in Immunology. doi: 10.3389/fimmu.2017.01221
3. Campos CB, Lavalle GE, Horta RS, Rodrigues AAM, Viana AAS, Carneiro RA (2011) Associação de cirurgia, quimioterapia e imunoterapia no tratamento de melanoma canino de cavidade oral – relato de dois casos. Veterinária e Zootecnia 18:80-85.
4. Caponero R (2018) Imunoterapia: métodos e aplicação no câncer. FEMAMA. Accessed on: March 13, 2021
5. Chang Y-H, Connolly J, Shimasaki N, Mimura K, Kono K, Campana D (2013) A chimeric receptor with NKG2D specificity enhances Natural Killer cell activation and killing of tumor cells. Cancer Research 73(6).
6. Chang DK, Peterson E, Sun J, Goudie C, Drapkin RI, Liu JF, Matulonis U, Zhu Q, Marasco WA (2016) Anti-CCR4 monoclonal antibody enhances anti-tumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model. Oncoimmunology. doi: 10.1080/2162402X.2015.1090075
7. Cicchelero L, Denies S, Haers H, Vanderperren K, Stock E, Brantegem LV, Rooster H, Sanders NN (2016) Intratumoural interleukin 12 gene therapy stimulates the immune system and decreases angiogenesis in dogs with spontaneous cancer. Veterinary and Comparative Oncology. doi: 10.1111/vco.12255
8. Du X, Zhang B, Hu F, Xie C, Tian H, Gu Q, Gong H, Bai X, Zhang J (2020) The therapeutic effects of intratumoral injection of IL12IL2GMCSF fusion protein on canine tumors. bioRxiv. doi: 10.1101/2020.06.03.131904
9. Flesner BK, Wood GW, Gayheart-Walsten P, Sonderegger FL, Henry CJ, Tate DJ, Bechtel SM, Donnelly LL, Johnson GC, Kim DY, Wahaus, TA, Bryan JN, Reyes N (2020) Autologous cancer cell vaccination, adoptive T-cell transfer, and interleukin- 2 administration results in long-term survival for companion dogs with osteosarcoma. Journal of Veterinary Internal Medicine. doi: 10.1111/jvim.15852
10. Fossum TW (2014) Cirurgia de pequenos animais. Rio de Janeiro.
11. Gavazza A, Lubas G, Fridman A, Peruzzi D, Impellizeri JA, Luberto L, Marra E, Roscilli G, Ciliberto G, Aurisicchio L (2013) Safety and Efficacy of a Genetic Vaccine Targeting Telomerase Plus Chemotherapy for the Therapy of Canine B-Cell Lymphoma. Human Gene Therapy. doi: 10.1089/hum.2013.112
12. Gentschev I, Patil SS, Adelfinger M, Weibel S, Geissinger U, Frentzen A, Chen NG, Yu YA, Zhang Q, Ogilvie G, Szalay AA (2013) Characterization and evaluation of a new oncolytic Vaccinia Virus strain LIVP6.1.1 for canine cancer therapy. Bioengineered. doi: 10.4161/bioe.22462
13. Hix LM, Shi YH, Brutkiewicz RR, Stein PL, Wang CR, Zhang M (2011) CD1d-Expressing Breast Cancer Cells Modulate NKT Cell-Mediated Antitumor Immunity in a Murine Model of Breast Cancer Metastasis. PLoS One. doi: 10.1371/journal.pone.0020702
14. Impellizeri JA, Gavazza A, Greissworth E, Crispo A, Montella M, Ciliberto G, Lubas G, Aurisicchio L (2018) Tel-eVax: a genetic vaccine targeting telomerase for treatment of canine lymphoma. Journal of Translational Medicine. doi: 10.1186/s12967-018-1738-6
15. João CF (2012) Imunoterapia com a vacina heteróloga de DNAHSP65+PROTEÍNA-HSP65 de Mycobacterium leprae em tumores mamários de cadelas. Thesis, Universidade Estadual Paulista.
16. Kalinski P, Urban J, Narang R, Berk E, Wieckowski E, Muthuswamy R (2009) Dendritic cell-based therapeutic cancer vaccines: what we have and what we need. Future Oncology. doi: 10.2217/FON.09.6
17. Kos S, Lopes A, Preat V, Cemazar M, Tratar UL, Ucakar B, Vanvarenberg K, Sersa G, Vandermeulen G (2019) Intradermal DNA vaccination combined with dual CTLA-4 and PD-1 blockade provides robust tumor immunity in murine melanoma. PLoS One. doi: 10.1371/journal.pone.0217762
18. Lee KM, An JH, Yang SJ, Park SM, Lee JH, Chae HK, Song WJ, Youn HY (2021) Influence of canine macrophage-derived extracellular vesicles on apoptosis in canine melanoma and osteosarcoma cell lines. Anticancer Research. doi: https://doi.org/10.21873/anticanres.14823
19. London CA, Gardner AH, Rippy S, Post G, Perle KL, Crew L, Lopresti-Morrow L, Garton AJ, McMahon G, LaVallee TM, Gedrich R (2017) KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells. Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-16-2152
20. Maekawa N, Konnai S, Takagi S, Kagawa Y, Okagawa T, Nishimori A, Ikebuchi R, Izumi Y, Deguchi T, Nakajima C, Kato Y, Yamamoto K, Uemura H, Suzuki Y, Murata S, Ohashi K (2017) A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma. Scientific Reports. doi: 10.1038/s41598-017-09444-2
21. Martins JLP (2018) Avaliação da utilização de imunoterapia com APAVAC® em cães e gatos com cancro – estudo retrospectivo de 20 casos. Dissertação, Universidade de Lisboa.
22. Mata M, Vera J, Gerken C, Rooney CM, Miller T, Pfent C, Wang LL, Wilson-Robles HM, Gottschalk S (2014) Towards immunotherapy with redirected T cells in a large animal model: Ex vivo activation, expansion, and genetic modification of canine T cells. Journal of Immunotherapy. doi:10.1097/CJI.0000000000000052
23. Matoso LML, Rosário SSD, Matoso MBL (2015) As estratégias de cuidados para o alívio dos efeitos colaterais da quimioterapia em mulheres. Saúde (Santa Maria). doi: 10592/22365834
24. O’Connor CM, Sheppard S, Hartline CA, Huls H, Johnson M, Palla SL, Maiti S, Ma W, Davis RE, Craig S, Lee DA, Champlin R, Wilson H, Cooper LJN (2012) Adoptive T-cell therapy improves treatment of canine non–Hodgkin lymphoma post chemotherapy. Scientific Reports. doi: 10.1038/srep00249
25. Panjwani MK, Smith JB, Schutsky K, Gnanandarajah J, O’Connor CM, Powell DJ Jr, Mason NJ (2016) Feasibility and safety of RNA-transfected CD20-specific chimeric antigen receptor T cells in dogs with spontaneous B cell lymphoma. Molecular Therapy. Doi: 10.1038/mt.2016.146
26. Regan D, Guth A, Coy J, Dow S (2016) Cancer immunotherapy in veterinary medicine: Current options and new developments. The Veterinary Journal. doi: 10.1016/j.tvjl.2015.10.008
27. Sato BYN (2017) Eficiência da imunoterapia no tratamento do linfoma de células B em cães. Universidade Estadual Paulista Júlio de Mesquita Filho. Accessed on: May 10, 2020
28. Shin JH, Zhang L, Murillo-Sauca O, Kim J, Kohrt HEK, Bui JD, Sunwoo JB (2013) Modulation of natural killer cell anti-tumor activity by the aryl hydrocarbon receptor. Proceedings of the National Academy of Sciences of the United States of America. doi: 10.1073/pnas.1302856110
29. Singer J, Fazekas J, Wang W, Weichselbaumer M, Matz M, Mader A, Steinfellner W, Meitz S, Mechtcheriakova D, Sobanov Y, Willmann M, Stockner T, Spillner E, Kunert R, Jensen-Jarolim E (2014) Generation of a Canine Anti-EGFR (ErbB-1) Antibody for Passive Immunotherapy in Dog Cancer Patients. Molecular Cancer Therapeutics. doi: 10.1158/1535-7163.MCT-13-0288
30. Smaletz O, Mutti HB (2015) Imunologia em cancerologia. In: Geller M, Scheinberg MA (eds) Diagnóstico e tratamento das doenças imunológicas. 2ed. Elsevier, Rio de Janeiro, pp 347-350.
31. Spezzia S (2016) O uso do bolus na radioterapia. Revista da Faculdade de Ciências Médicas de Sorocaba. doi: 10.5327/Z1984-4840201623688
32. Srisawat W, Nambooppha B, Pringproa K, Thongtharb A, Prachasilchai W, Sthitmatee N (2020) A preliminary study of the cross-reactivity of canine MAGE-A with hominid monoclonal antibody 6C1 in canine mammary gland tumors: an attractive target for cancer diagnostic, prognostic and immunotherapeutic development in dogs. Veterinary Sciences. doi: 10.3390/vetsci7030109
33. Tagawa M, Maekawa N, Konnai S, Takagi S (2016) Evaluation of costimulatory molecules in peripheral blood lymphocytes of canine patients with histiocytic sarcoma. PLoS One, doi: 10.1371/journal.pone.0150030
34. Tagawa M, Kurashima C, Tagaki S, Maekawa N, Konnai S, Shimbo G, Matsumoto K, Inokuma H, Kawamoto K, Miyahara K (2018) Evaluation of costimulatory molecules in dogs with B cell high grade lymphoma. PLoS One. doi: 10.1371/journal.pone.0201222
35. Thamm DH, Kurzman ID, Clark MA, Ehrhart EJ III, Kraft SL, Gustafson DL, Vail DM (2010) Preclinical investigation of PEGylated tumor necrosis factor α in dogs with spontaneous tumors: phase I evaluation. Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-09-2804
36. Wycislo KL, Fan TM (2015) The Immunotherapy of Canine Osteosarcoma: A Historical and Systematic Review. Journal of Veterinary Internal Medicine. doi: 10.1111/jvim.12603
37. Yazawa N, Hamaguchi Y, Poe JC, Tedder TF (2005) Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proceedings of the National Academy of Sciences of the United States of America. Accessed on: October 9, 2020.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

How to cite

Schoenfelder, A. T., Belarmino, L. A., & Batista, K. Z. S. (2021). Anti-tumor immunotherapy in veterinary medicine. Multidisciplinary Reviews, 4, 2021010. https://doi.org/10.29327/multi.2021010

[1] Berger M (2005) Estudo de fase I com vacina celular autóloga imunomodulada para tratamento de câncer de próstata localmente avançado ou metastático. Thesis, Universidade Federal do Rio Grande do Sul.

[2] Bowers JS, Majchrzak K, Nelson MH, Aksoy BA, Wyatt MM, Smith, AS, Bailey SR, Neal LR, Hammerbacher JE, Paulos CM (2017) PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T Cells. Frontiers in Immunology. doi: 10.3389/fimmu.2017.01221

[3] Campos CB, Lavalle GE, Horta RS, Rodrigues AAM, Viana AAS, Carneiro RA (2011) Associação de cirurgia, quimioterapia e imunoterapia no tratamento de melanoma canino de cavidade oral – relato de dois casos. Veterinária e Zootecnia 18:80-85.

[4] Caponero R (2018) Imunoterapia: métodos e aplicação no câncer. FEMAMA. Accessed on: March 13, 2021

[5] Chang Y-H, Connolly J, Shimasaki N, Mimura K, Kono K, Campana D (2013) A chimeric receptor with NKG2D specificity enhances Natural Killer cell activation and killing of tumor cells. Cancer Research 73(6).

[6] Chang DK, Peterson E, Sun J, Goudie C, Drapkin RI, Liu JF, Matulonis U, Zhu Q, Marasco WA (2016) Anti-CCR4 monoclonal antibody enhances anti-tumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model. Oncoimmunology. doi: 10.1080/2162402X.2015.1090075

[7] Cicchelero L, Denies S, Haers H, Vanderperren K, Stock E, Brantegem LV, Rooster H, Sanders NN (2016) Intratumoural interleukin 12 gene therapy stimulates the immune system and decreases angiogenesis in dogs with spontaneous cancer. Veterinary and Comparative Oncology. doi: 10.1111/vco.12255

[8] Du X, Zhang B, Hu F, Xie C, Tian H, Gu Q, Gong H, Bai X, Zhang J (2020) The therapeutic effects of intratumoral injection of IL12IL2GMCSF fusion protein on canine tumors. bioRxiv. doi: 10.1101/2020.06.03.131904

[9] Flesner BK, Wood GW, Gayheart-Walsten P, Sonderegger FL, Henry CJ, Tate DJ, Bechtel SM, Donnelly LL, Johnson GC, Kim DY, Wahaus, TA, Bryan JN, Reyes N (2020) Autologous cancer cell vaccination, adoptive T-cell transfer, and interleukin- 2 administration results in long-term survival for companion dogs with osteosarcoma. Journal of Veterinary Internal Medicine. doi: 10.1111/jvim.15852

[10] Fossum TW (2014) Cirurgia de pequenos animais. Rio de Janeiro.

[11] Gavazza A, Lubas G, Fridman A, Peruzzi D, Impellizeri JA, Luberto L, Marra E, Roscilli G, Ciliberto G, Aurisicchio L (2013) Safety and Efficacy of a Genetic Vaccine Targeting Telomerase Plus Chemotherapy for the Therapy of Canine B-Cell Lymphoma. Human Gene Therapy. doi: 10.1089/hum.2013.112

[12] Gentschev I, Patil SS, Adelfinger M, Weibel S, Geissinger U, Frentzen A, Chen NG, Yu YA, Zhang Q, Ogilvie G, Szalay AA (2013) Characterization and evaluation of a new oncolytic Vaccinia Virus strain LIVP6.1.1 for canine cancer therapy. Bioengineered. doi: 10.4161/bioe.22462

[13] Hix LM, Shi YH, Brutkiewicz RR, Stein PL, Wang CR, Zhang M (2011) CD1d-Expressing Breast Cancer Cells Modulate NKT Cell-Mediated Antitumor Immunity in a Murine Model of Breast Cancer Metastasis. PLoS One. doi: 10.1371/journal.pone.0020702

[14] Impellizeri JA, Gavazza A, Greissworth E, Crispo A, Montella M, Ciliberto G, Lubas G, Aurisicchio L (2018) Tel-eVax: a genetic vaccine targeting telomerase for treatment of canine lymphoma. Journal of Translational Medicine. doi: 10.1186/s12967-018-1738-6

[15] João CF (2012) Imunoterapia com a vacina heteróloga de DNAHSP65+PROTEÍNA-HSP65 de Mycobacterium leprae em tumores mamários de cadelas. Thesis, Universidade Estadual Paulista.

[16] Kalinski P, Urban J, Narang R, Berk E, Wieckowski E, Muthuswamy R (2009) Dendritic cell-based therapeutic cancer vaccines: what we have and what we need. Future Oncology. doi: 10.2217/FON.09.6

[17] Kos S, Lopes A, Preat V, Cemazar M, Tratar UL, Ucakar B, Vanvarenberg K, Sersa G, Vandermeulen G (2019) Intradermal DNA vaccination combined with dual CTLA-4 and PD-1 blockade provides robust tumor immunity in murine melanoma. PLoS One. doi: 10.1371/journal.pone.0217762

[18] Lee KM, An JH, Yang SJ, Park SM, Lee JH, Chae HK, Song WJ, Youn HY (2021) Influence of canine macrophage-derived extracellular vesicles on apoptosis in canine melanoma and osteosarcoma cell lines. Anticancer Research. doi: https://doi.org/10.21873/anticanres.14823

[19] London CA, Gardner AH, Rippy S, Post G, Perle KL, Crew L, Lopresti-Morrow L, Garton AJ, McMahon G, LaVallee TM, Gedrich R (2017) KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells. Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-16-2152

[20] Maekawa N, Konnai S, Takagi S, Kagawa Y, Okagawa T, Nishimori A, Ikebuchi R, Izumi Y, Deguchi T, Nakajima C, Kato Y, Yamamoto K, Uemura H, Suzuki Y, Murata S, Ohashi K (2017) A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma. Scientific Reports. doi: 10.1038/s41598-017-09444-2

[21] Martins JLP (2018) Avaliação da utilização de imunoterapia com APAVAC® em cães e gatos com cancro – estudo retrospectivo de 20 casos. Dissertação, Universidade de Lisboa.

[22] Mata M, Vera J, Gerken C, Rooney CM, Miller T, Pfent C, Wang LL, Wilson-Robles HM, Gottschalk S (2014) Towards immunotherapy with redirected T cells in a large animal model: Ex vivo activation, expansion, and genetic modification of canine T cells. Journal of Immunotherapy. doi:10.1097/CJI.0000000000000052

[23] Matoso LML, Rosário SSD, Matoso MBL (2015) As estratégias de cuidados para o alívio dos efeitos colaterais da quimioterapia em mulheres. Saúde (Santa Maria). doi: 10592/22365834

[24] O’Connor CM, Sheppard S, Hartline CA, Huls H, Johnson M, Palla SL, Maiti S, Ma W, Davis RE, Craig S, Lee DA, Champlin R, Wilson H, Cooper LJN (2012) Adoptive T-cell therapy improves treatment of canine non–Hodgkin lymphoma post chemotherapy. Scientific Reports. doi: 10.1038/srep00249

[25] Panjwani MK, Smith JB, Schutsky K, Gnanandarajah J, O’Connor CM, Powell DJ Jr, Mason NJ (2016) Feasibility and safety of RNA-transfected CD20-specific chimeric antigen receptor T cells in dogs with spontaneous B cell lymphoma. Molecular Therapy. Doi: 10.1038/mt.2016.146

[26] Regan D, Guth A, Coy J, Dow S (2016) Cancer immunotherapy in veterinary medicine: Current options and new developments. The Veterinary Journal. doi: 10.1016/j.tvjl.2015.10.008

[27] Sato BYN (2017) Eficiência da imunoterapia no tratamento do linfoma de células B em cães. Universidade Estadual Paulista Júlio de Mesquita Filho. Accessed on: May 10, 2020

[28] Shin JH, Zhang L, Murillo-Sauca O, Kim J, Kohrt HEK, Bui JD, Sunwoo JB (2013) Modulation of natural killer cell anti-tumor activity by the aryl hydrocarbon receptor. Proceedings of the National Academy of Sciences of the United States of America. doi: 10.1073/pnas.1302856110

[29] Singer J, Fazekas J, Wang W, Weichselbaumer M, Matz M, Mader A, Steinfellner W, Meitz S, Mechtcheriakova D, Sobanov Y, Willmann M, Stockner T, Spillner E, Kunert R, Jensen-Jarolim E (2014) Generation of a Canine Anti-EGFR (ErbB-1) Antibody for Passive Immunotherapy in Dog Cancer Patients. Molecular Cancer Therapeutics. doi: 10.1158/1535-7163.MCT-13-0288

[30] Smaletz O, Mutti HB (2015) Imunologia em cancerologia. In: Geller M, Scheinberg MA (eds) Diagnóstico e tratamento das doenças imunológicas. 2ed. Elsevier, Rio de Janeiro, pp 347-350.

[31] Spezzia S (2016) O uso do bolus na radioterapia. Revista da Faculdade de Ciências Médicas de Sorocaba. doi: 10.5327/Z1984-4840201623688

[32] Srisawat W, Nambooppha B, Pringproa K, Thongtharb A, Prachasilchai W, Sthitmatee N (2020) A preliminary study of the cross-reactivity of canine MAGE-A with hominid monoclonal antibody 6C1 in canine mammary gland tumors: an attractive target for cancer diagnostic, prognostic and immunotherapeutic development in dogs. Veterinary Sciences. doi: 10.3390/vetsci7030109

[33] Tagawa M, Maekawa N, Konnai S, Takagi S (2016) Evaluation of costimulatory molecules in peripheral blood lymphocytes of canine patients with histiocytic sarcoma. PLoS One, doi: 10.1371/journal.pone.0150030

[34] Tagawa M, Kurashima C, Tagaki S, Maekawa N, Konnai S, Shimbo G, Matsumoto K, Inokuma H, Kawamoto K, Miyahara K (2018) Evaluation of costimulatory molecules in dogs with B cell high grade lymphoma. PLoS One. doi: 10.1371/journal.pone.0201222

[35] Thamm DH, Kurzman ID, Clark MA, Ehrhart EJ III, Kraft SL, Gustafson DL, Vail DM (2010) Preclinical investigation of PEGylated tumor necrosis factor α in dogs with spontaneous tumors: phase I evaluation. Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-09-2804

[36] Wycislo KL, Fan TM (2015) The Immunotherapy of Canine Osteosarcoma: A Historical and Systematic Review. Journal of Veterinary Internal Medicine. doi: 10.1111/jvim.12603

[37] Yazawa N, Hamaguchi Y, Poe JC, Tedder TF (2005) Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proceedings of the National Academy of Sciences of the United States of America. Accessed on: October 9, 2020.

Abstract

References

How to cite